Catheter Precision (VTAK) announced that LockeT sales for Q2 2025 are on track to be the highest to date. Second quarter 2025 LockeT sales are already outpacing Q2 2024 sales with a 200% increase. Catheter Precision now has several US hospitals that are on track to issue more than $100,000 in purchase orders each for LockeT by the end of 2025. These hospitals include Montefiore, Eisenhower Health, and Overland Park Regional Medical Center.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTAK:
- Catheter Precision Stock (VTAK) Rockets 170% on a Delayed Investor Reaction
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories
- Catheter Precision secures VIVO purchase order
- Catheter Precision Approves Warrant Issuance to Ladenburg
- Catheter Precision Announces CCO Departure and Leadership Change
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue